Abstract:
The aim of this study was to formulate, characterize and evaluation of solid lipid ‎nanoparticles (SLNs) of practically insoluble bromocriptine mesylate to enhance ‎its solubility and to improve its oral bioavailability by avoiding first pass effect as ‎well as to produce control release action of the drug from the SLNs for an efficient ‎management of Parkinson’s Disease in addition to an improvement of the patient ‎compliance. The SLNs were prepared by the Emulsification-Solvent Evaporation ‎method using glycerylbehenate as lipid and pluronic F-68 were used as stabilizer ‎and Ethanol and chloroform used as a solvent. The prepared SLNs then tested for ‎entrapment efficiency, solubility analysis, in vitro drug release then characterize ‎‎(Scanning Electron Microscope (SEM), particle size distribution, zeta potential) ‎and evaluate their flow property, uniformity of weight, in vitro disintegration test, ‎drug content, in vitro drug release, release kinetics, in vivo studies and stability ‎studies of optimized SLNs and filled in Hard Gelatin Capsules (HGC). The SLNs ‎release the drug in contolled manner upto 12hrs. From the animal study, it was ‎concluded that the group treated with optimized SLN.G5 showed better and ‎sustained reduction in parkinson’s symptoms as compared to control group and ‎the group treated with pure drug formulation, indicated improvement in ‎bioavailability of drug.‎

Keywords: Bromocriptine Mesylate, SLNs, Emulsification-Solvent Evaporation, Bioavailability, Pharmacodynamic Study.